newsfilter.io

Diagnostics & Research — industry outlook

  • Period: 2026-10-19 to 2026-11-09
  • Events: 18
  • Generated: 2026-11-09T07:30:00.003Z

Financial Guidance & Revenue Trajectory
Diagnostics & Research leaders have largely raised or reaffirmed 2026 revenue and earnings guidance, signaling a broad-based recovery in demand and pricing power, though long-term 2027 targets remain variable. Medpace (MEDP) raised 2026 revenue guidance to $2.835 billion to $2.855 billion (12%–12.8% growth) and EBITDA to $638 million to $652 million, attributing the upside to normalized cancellation patterns and record Q4 awards. IQVIA (IQV) increased 2026 revenue guidance to $17.35B–$17.50B (6.4%–7.3% growth) and adjusted EBITDA to $4.025B–$4.055B, driven by strong clinical bookings and commercial growth. Labcorp (LH) raised enterprise revenue growth to 5.9% to 6.7% and adjusted EPS to $18.30 to $18.70, citing strong biopharma demand and M&A accretion. Revvity (RVTY) raised pro forma organic growth to 5% and full-year revenue to $2.86 billion, marking three consecutive quarters of guidance increases. Thermo Fisher (TMO) raised FY2026 revenue to $47.7–$48.2 billion (7–8% reported, 4% organic) and adjusted EPS to $25.13–$25.43 (10–11% growth), viewing 7% organic growth as a "not a cap" baseline. Guardant (GH) raised FY2026 revenue to $1.36–$1.37 billion (38–40% growth) and screening revenue to $233–$238 million. NeoGenomics (NEO) raised 2026 revenue to $807–$809 million (11% growth) and adjusted EBITDA to $60 million. Castle (CSTL) raised FY2026 revenue to $385–$395 million, driven by TissueCipher growth. Fulgent (FLGT) reaffirmed revenue at $330–$340 million (2.3%–5.4% growth) but narrowed EPS loss guidance to $1.65–$1.75. Natera (NTRA) raised FY2026 revenue to $3.005B–$3.035B and projects $6 billion revenue by 2029. QuidelOrtho (OCDX) narrowed guidance to $2.50B–$2.52B for FY2026 due to China destocking. Myriad (MYGN) raised FY2026 revenue midpoint to $785 million (range $780–$790 million).

Operational Margins & Cost Management
Companies are prioritizing margin expansion through operational efficiency, AI adoption, and cost transformation, though some face near-term headwinds from restructuring or capacity investments. Medpace (MEDP) expects 2026 EBITDA margins to remain strong in Q4 but faces a headwind in 2027 from a $20 million expansion cost in Cincinnati. IQVIA (IQV) targets flat adjusted EBITDA margins at ~23.2%, relying on AI-driven automation to offset pass-through mix headwinds and currency. Labcorp (LH) expects enterprise margin expansion via "Launchpad" initiatives targeting $125 million in savings. Revvity (RVTY) raised full-year pro forma operating margin to 28.8% and expects a 40%+ incremental margin framework to remain sustainable. Thermo Fisher (TMO) assumes 80 basis points of adjusted operating margin expansion for FY2026. Guardant (GH) expects a 65% non-GAAP gross margin and targets a $200 Shield cost per test by end of 2028. Charles River (CRL) expects a 120–150 basis points operating margin expansion for 2026 and a $300 million cost savings program ("Create the Future") to drive 2027 improvement. Myriad (MYGN) anticipates >500 basis points gross margin improvement post-divestiture. QuidelOrtho (OCDX) projects $80 million in annual savings starting 2027 from a new cost transformation program, though Q4 2026 FCF faces one-time restructuring charges of $30 million–$35 million. Fulgent (FLGT) expects non-GAAP operating margins in the low negative 20% range, with non-GAAP gross margins in the mid-30% range.

Market Demand, Pacing, and Sector Mix
The industry is observing a bifurcated demand recovery, with robust growth in biotech funding and clinical trial start-ups offset by specific softness in China and early-stage biotech. Medpace (MEDP) reports "high-quality" RFP activity and strong initial awards, with cancellations now driven primarily by product failure rather than funding constraints. IQVIA (IQV) notes EBP funding at $90 billion YTD (up 85% YoY), with clinical trial starts up in the high single digits and RDS net new bookings up 14%. Charles River (CRL) cites biotech funding at $100 billion (trailing 12-month) and a DSA book-to-bill ratio of 1.09x. Thermo Fisher (TMO) highlights strong demand in pharma & biotech and bioproduction, while academic/government remains flat. Natera (NTRA) reports Signatera clinical MRD units growing 56% YoY and Pharma & Data Services up 70% in the first three quarters, driven by MRD-guided trials. Revvity (RVTY) sees a fundamental recovery in pharma/biotech spending, though China reproductive health faces headwinds due to declining birth rates. QuidelOrtho (OCDX) faces near-term pressure from China destocking, with China revenue share dropping to 4%–5% in 2027 due to IVD pricing guidelines. Guardant (GH) notes volume growth of >50% in Oncology and 30% in Garden 360 Liquid, driven by new FDA approvals and payer decisions. Labcorp (LH) sees organic revenue growth driven by Central Lab Services in oncology and cardiometabolic sectors. NeoGenomics (NEO) expects NGS revenue to grow >25%, with a mix shift toward high-value large panels. Castle (CSTL) projects TissueCipher volume growth of 50%–52%, though DecisionDX Melanoma growth is revised to mid-single digits.

AI Integration & Technological Catalysts
AI is being deployed as a primary differentiator for operational efficiency, drug discovery acceleration, and diagnostic workflow automation, rather than a simple revenue line item. IQVIA (IQV) has deployed 415 AI agents, viewing them as a win-rate differentiator and expecting AI-driven automation to drive ~80 bps of operational margin expansion. Thermo Fisher (TMO) embeds AI in microscopes to reduce manual setup by ~90% and launched an AI-based clinical research assistant, anticipating AI will drive a "virtuous cycle" of lab in the loop concepts. Medpace (MEDP) notes that AI is a "change agent" within 1–2 years for feasibility planning and document authoring. Revvity (RVTY) highlights new AI-native software launches (LabGistics, Signals AI) and expects AI demand to expand beyond high-content screening to impact reagents and instruments. Guardant (GH) utilizes "Infinity AI" for decision support and real-world evidence generation, analyzing >1.5 million patient tests. Labcorp (LH) is deploying the "Next Gen LabCorp Global Trial Connect" and robotics to enhance efficiency. NeoGenomics (NEO) has a strategic partnership with Indica Labs for AI-driven digital pathology and expects a transition to NovaSeq X sequencers in H1 2027. Fulgent (FLGT) plans to deploy five additional AI applications in Q4 2026, with an AI platform analyzing 255,000 slides in Q3.

Regulatory Reimbursement & PAMA Impact
A dominant theme involves the management of PAMA fee schedule cuts, Medicare coverage decisions, and FDA approvals, which are creating short-term financial pressure but long-term growth opportunities. Labcorp (LH) identifies the 2027 implementation of PAMA as the industry's "toughest year," with an estimated $125 million impact expected to be offset by business momentum. Myriad (MYGN) faces 1% to 5% annual ASP declines in Hereditary Cancer Testing due to payer friction, while Natera (NTRA) expects 9–10 additional MolDX submissions to resolve soon, expanding its TAM. Guardant (GH) faces a $10–$15 million FCF shift to 2027 due to CMS claims processing delays for new liquid CDX codes and targets $200 Shield cost per test by 2028. QuidelOrtho (OCDX) expects provincial implementation of China IVD pricing guidelines in 2027 to cause significant volume and pricing pressure. Grail (GRAL) is awaiting an FDA decision on GALLERY by early Q1 2027, viewing approval as the "gateway" to Medicare reimbursement. NeoGenomics (NEO) anticipates 2027 Medicare rates will have a "relatively low" impact (low to mid-single digit millions), expecting AUP growth to offset fee cuts. Castle (CSTL) awaits a final CMS pricing decision for Advanced ADTX in December 2026 to determine 2027 ASPs.

M&A Activity, Capacity Expansion, and Strategic Pivot
Companies are actively acquiring complementary capabilities, divesting low-growth segments, and expanding capacity to meet the accelerating demand in MRD and biopharma services. Labcorp (LH) announced acquisitions of BioReference ($250 million revenue impact), Myriad Genetics Prenatal ($160 million revenue impact), and MLM Medical Labs, while divesting to offset PAMA costs. Myriad (MYGN) signed a definitive agreement to sell its Prenatal Health business to LabCorp for $210 million plus inventory to sharpen focus on cancer care. Grail (GRAL) closed a $110 million financing round with Samsung and expanded its sales force from 90 to 120 representatives. Natera (NTRA) appointed a new CEO (Solomon Moscovich), stepped down Steve Chapman, and is investing in $1.3 billion in R&D for 2026 to support MRD and FIND study costs. Charles River (CRL) is divesting a CDMO business and expanding bioanalytical capacity via five organic expansions. Revvity (RVTY) plans to divest its China immunodiagnostics business next year to focus on high-content screening. Medpace (MEDP) approved a new $1 billion share repurchase authorization and is adding $20 million in operating costs for a Cincinnati expansion.

Geographic Exposure & China Dynamics
Geographic divergence is sharp, with significant growth in China for R&D services and early-phase trials, contrasted by structural pricing pressures and destocking in China for in vitro diagnostics (IVD). IQVIA (IQV) and IQV panelists note China's share of sponsor headquarters rising from 17% (2016) to 43% (2025), with China solidifying its position as a global R&D hub. However, Thermo Fisher (TMO) expects low double-digit growth in China but notes biotech reagent demand is muted. Revvity (RVTY) reports APAC growth is negatively impacted by reproductive health pressures in China. QuidelOrtho (OCDX) faces its most significant headwinds here, with China revenue share dropping to 4%–5% in 2027 due to nationwide IVD pricing guidelines. Conversely, Natera (NTRA) is launching Signatera in Japan with Colorectal and Bladder indications, expecting fast adoption.

Leadership Changes & Corporate Strategy
Several companies are undergoing significant leadership transitions or strategic pivots to align with long-term growth and profitability goals. NeoGenomics (NEO) will have Warren Stone become CEO effective January 4, 2027, with a focus on "higher value advanced testing modalities" and a transition to the NovaSeq X platform. Natera (NTRA) has transitioned from Steve Chapman to Solomon Moscovich as CEO to lead the push toward the $6 billion 2029 revenue target. Acclaris (ACRS) is pivoting its ATI-052 development priority from Atopic Dermatitis to Eosinophilic Esophagitis (EOE) to maximize capital efficiency and fund a $50 million top-up financing. Fulgent (FLGT) is completing the integration of BACO Diagnostics and StrataDx, while Myriad (MYGN) is executing its ASCEND operational modernization to improve margins post-divestiture.